Traws Pharma reports positive Phase 1 data for COVID-19 drug ratutrelvir; no ritonavir needed

Traws Pharma, Inc.

Phase 1 data at 600 mg/day for 10 days show trough blood levels ~13x EC50 and >EC90 for 2 days post-treatment.
Ratutrelvir suppressed 18 SARS-CoV-2 strains including nirmatrelvir-resistant and Omicron variants in lab tests.
No requirement for ritonavir boosting due to favorable metabolism, potentially reducing drug-drug interaction risks.
Excellent safety/tolerability in SAD and MAD studies at all doses tested; target Phase 2 dose defined.
Company plans FDA interactions to initiate Phase 2; investor event March 31, 2025 at 10:00 AM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.